421PPreliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors. (23rd October 2018) - Johnson, M; Galsky, M; Barve, M; Goel, S; Park, H; Du, B; Mu, S; Ramakrishnan, V; Wood, K; Wang, V; Lakhani, N